Hair Loss Treatment With PRP: The Mechanism-to-Candidacy Framework That Separates Who Benefits From Who Needs a Different Plan
Introduction: Beyond the 70-80% Success Rate Myth
Most online content about platelet-rich plasma (PRP) for hair loss reduces a nuanced regenerative therapy to a simple yes-or-no question: does it work? The answer usually arrives as a “70-80% success rate.” That figure is repeated across clinic blogs with no source, no stage of hair loss attached, and no explanation of how the PRP was prepared or delivered.
PRP’s real value only becomes clear when the discussion moves through four steps:
- Biology: how the treatment acts on the follicle
- Evidence: what current research actually shows
- Candidacy: which patients fit, based on clinical staging
- Strategy: where PRP belongs within a broader treatment plan
This article follows that path. It covers the mechanism, the 2025 research data, Norwood and Ludwig staging, transparency about FDA off-label status, and PRP’s role as an adjunct rather than a standalone cure. The perspective comes from Charles Medical Group, a physician-led practice that has focused exclusively on hair restoration for more than 25 years. Because the practice offers medication, device-based therapy, and surgery, it does not need every patient to fit a single service.
The Biology: How PRP Works on Hair Follicles
PRP is a concentrated preparation of the patient’s own platelets. A small sample of blood is drawn and spun in a centrifuge, which separates the platelet-rich layer from the other components. That concentrate is then injected into the scalp, where it delivers growth factors directly to the follicles.
The Growth Factors Driving the Effect
Platelets carry signaling proteins that influence follicle behavior:
- PDGF (platelet-derived growth factor): promotes cell proliferation
- VEGF (vascular endothelial growth factor): increases blood supply to follicles
- EGF (epidermal growth factor): supports cellular growth and repair
- IGF-1 (insulin-like growth factor 1): helps sustain the growth phase
Together, these factors stimulate stem cells in the hair follicle bulge. In susceptible follicles, they can help reverse miniaturization, the progressive shrinking that defines pattern hair loss, by reactivating dormant or weakened follicular units. PRP does not change a person’s genetic predisposition to hair loss. It works on the follicles that remain, not on the inherited process driving the loss.
Platelet Concentration Thresholds: Why Preparation Quality Matters
Clinically meaningful PRP typically concentrates platelets to four to seven times baseline blood levels. Preparations below that range are likely to deliver too little growth factor activity to have a therapeutic effect.
Preparation systems also vary widely, including centrifugation speed, spin cycles, and whether and how platelets are activated before injection. This variability is a major reason outcomes differ across studies and clinics, and consumer-facing content rarely discloses it. Two clinics can both advertise “PRP” while delivering very different products.
The Anagen/Telogen Shift: What PRP Changes
A healthy scalp keeps 85 to 90 percent of its follicles in anagen (the growth phase) and 10 to 15 percent in telogen (the resting and shedding phase). Pattern hair loss tips this balance toward shorter growth cycles and finer hairs.
PRP works by shortening telogen and extending anagen. It shifts the hair cycle; it does not permanently alter the follicle’s structure or genetics.
The exact mechanism is not yet fully understood. Current research suggests PRP increases anti-apoptotic proteins and reduces pro-apoptotic factors, which helps follicles survive and function longer. Clinicians who acknowledge this uncertainty are describing the science accurately.
What the 2025 Evidence Shows (and Doesn’t Show)
The largest current dataset is a 2025 systematic review and meta-analysis published in Dermatology and Therapy. It identified 43 randomized controlled trials covering 1,877 participants assessing PRP in alopecia. The authors concluded that moderate-quality evidence shows PRP is safe and effective for improving hair density, reducing hair loss, and enhancing clinical outcomes and patient satisfaction.
The same pooled analysis also found that PRP did not significantly affect hair thickness. Competitor content usually leaves this out, and it is a meaningful limitation on blanket claims that “it works.”
Mayo Clinic’s randomized controlled trial of 19 women with female pattern baldness found that PRP regrew hair about as well as other treatments on the market. The researchers concluded there is now scientific evidence that PRP works to temporarily regrow hair. That word is important. Results depend on the hair cycle and require ongoing maintenance. PRP is not a one-time cure.
Protocol variability remains the field’s core limitation. Outcomes depend on preparation method, injection technique, and treatment frequency, so not all “PRP treatment” is clinically equivalent. Effects on absolute hair count are inconsistent across studies, and thickness gains are not reliably demonstrated. Patients should understand these limits before they consider candidacy.
Stage-Specific Candidacy: Who Benefits From PRP
Phrases like “early to moderate hair loss” are too vague to guide treatment decisions. Clinicians use standardized scales instead:
- Norwood scale for men
- Ludwig scale for women
The reasoning is straightforward. PRP acts on follicles that are still present but weakened. It cannot regenerate follicles that have scarred over or disappeared entirely.
Good Candidates: Norwood I-III and Ludwig I-II
Patients in these stages have early-to-moderate androgenetic alopecia. They still have thinner, shorter, miniaturizing hairs, which are the tissue PRP’s growth factors can act on.
Skilled clinicians confirm candidacy with trichoscopy-based miniaturization assessment, a magnified examination of the scalp and hair shafts. This shows what proportion of follicles are miniaturizing, which a mirror or a photo cannot reveal.
When patients are properly staged and selected, sex does not appear to change the response. A 56-patient outcomes study found no statistically significant difference in treatment response between male and female pattern hair loss.
Poor Candidates: Advanced Loss, Scarring Alopecia, and Unrealistic Expectations
- Advanced pattern loss (Norwood V-VII): Too few viable miniaturizing follicles remain for PRP alone to produce a meaningful change.
- Scarring (cicatricial) alopecias: These are generally unresponsive because the follicular stem cell niche has been destroyed. Charles Medical Group offers tailored solutions for alopecia patients when PRP alone is not appropriate.
- Transplant-level expectations: Patients who expect PRP alone to restore density comparable to a hair transplant will be disappointed. For these patients, referral to a combination or surgical plan is essential.
The FDA Reality: Full Transparency on Off-Label Use
Several PRP preparation systems are FDA-cleared for orthopedic indications, such as bone grafts. Their use for hair growth is off-label, because no data sufficient for clearance of this indication has been submitted to the FDA. The International Society of Hair Restoration Surgery (ISHRS) confirms this status. It applies across the industry and is not a concern specific to any one provider.
Off-label does not mean unapproved or unsafe. It means the hair restoration use has not gone through the same FDA review pathway as the device’s originally cleared purpose. Many clinic websites blur this distinction or leave it out. Physicians who state the off-label status clearly earn more trust than those who imply FDA “approval” for hair restoration.
Safety Profile: What Patients Should Realistically Expect
PRP is autologous, meaning it is made from the patient’s own blood. This minimizes the risk of rejection or allergic reaction compared with synthetic injectables.
A review of 210 PRP and microneedling procedures in the Journal of the American Academy of Dermatology reported:
- Scalp itching: about 14% of cases
- Transient hair shedding: about 1.4%
- Lymphadenopathy (swollen lymph nodes): under 2%
These effects were generally mild and resolved on their own. The same review recommended that PRP be avoided in patients with active autoimmune disease, based on a documented case of serum sickness. A thorough medical history and screening by a physician, rather than a med-spa intake form, should come before any treatment.
Where Competitor Content Stops: PRP as an Adjunct, Not a Standalone Cure
The strongest evidence for PRP comes from using it within a combination protocol, not as a monotherapy. Most single-modality providers never address this. The research supports three combination pathways.
PRP Plus Medical Therapy (Minoxidil/Finasteride)
In a split-scalp randomized controlled trial, combination treatment increased hair density 2.9 times compared with PRP alone and 1.74 times compared with minoxidil alone. This finding is rarely reported in consumer content.
The two approaches work through different mechanisms. Medication addresses hormone-driven (DHT) miniaturization throughout the body, while PRP provides localized growth factor stimulation at the scalp. Charles Medical Group already uses Propecia® (finasteride) and Rogaine® (minoxidil) as foundational therapies, and these can be coordinated with PRP in a single plan.
PRP Plus Low-Level Laser Therapy (LLLT)
LLLT works through photobiomodulation: light energy that supports cellular energy production and may extend the anagen phase through a different pathway than PRP. LaserCap® therapy can serve as a home-based maintenance tool that extends the benefit between in-office PRP sessions. This combination suits patients who want to maximize non-surgical density gains before considering a transplant.
PRP as Surgical Synergy: Enhancing Transplant Outcomes
A 2025 systematic review of PRP as an adjunct to hair transplantation found that, across all included studies, adding PRP was associated with increased hair density, better follicle survival, and earlier onset of hair growth. Six of the nine studies reported significant density improvements, and five showed increased hair count.
A prospective comparative study found that patients who received PRP together with minoxidil, finasteride or spironolactone, and FUE achieved significantly better follicle survival, growth rates, and hair strength than controls. In this setting, PRP improves graft outcomes rather than replacing the procedure. This is the context of Charles Medical Group’s surgical work, including FUE, FUG/FUT, and the ARTAS® robotic system, and it is where PRP shows its best-supported, highest-impact results.
What a Combination Protocol Timeline Looks Like
Cleveland Clinic describes a standard PRP schedule for hair loss:
- Initial phase: one treatment per month for three months
- Consolidation phase: one treatment every three months for a year
- Maintenance phase: one treatment per year
PRP is not a one-time treatment. Because it modulates the hair cycle rather than providing a permanent cure, maintenance sessions are needed to sustain the anagen-extension effect. This schedule runs alongside any medication and includes periodic reassessment, since a patient’s Norwood or Ludwig stage can progress and change what makes sense. Patients should view PRP as a long-term care commitment, best guided by a physician who can adjust the protocol as their hair loss evolves.
Why Single-Solution Providers Fall Short
The med-spa model often sells PRP on its own, frequently delivered by non-physician staff and backed by generic success-rate claims. A physician-led, multi-modality practice works in the opposite order: it stages candidacy first and then builds a coordinated plan.
The gap is mostly diagnostic. Clinics without surgical or long-term hair restoration expertise are less likely to use trichoscopy-based staging. They are also less likely to recognize when a patient should be directed toward a transplant or away from PRP altogether.
Charles Medical Group represents the alternative. Dr. Glenn Charles has practiced exclusively in hair restoration for more than 25 years and has performed over 15,000 procedures. He is Past President of the American Board of Hair Restoration Surgery, a Fellow of ISHRS, and the author and editor of Hair Transplantation and Hair Transplant 360, two of the field’s most widely recognized textbooks. That depth of experience supports honest, conservative assessments, including telling a patient when PRP alone is not the right plan.
A Practical Self-Assessment: Who Is Likely a Candidate?
The following framework can help readers estimate where they fall. It is not a diagnosis.
- Stage of loss: Early thinning and a widening part suggest a better fit. Clearly visible scalp or an advanced pattern suggests a combination or surgical plan.
- Rate of recent shedding: Active, recent shedding may indicate follicles that are still responsive.
- Miniaturized versus lost follicles: Fine, wispy hairs signal follicles that may respond. Smooth, bare areas suggest follicles that are gone.
- Treatment goals: Improving density favors PRP-based protocols. Full restoration usually requires surgery.
Only an in-person or virtual consultation with trichoscopic evaluation can confirm staging and true candidacy. Charles Medical Group offers complimentary consultations, including virtual appointments by FaceTime and Skype, as a simple next step for readers unsure of their stage.
Conclusion: PRP’s Real Value Lies in the Right Plan, Not a Standalone Promise
PRP acts through a real biological mechanism, even though the science is still maturing. The 2025 meta-analysis supports benefits for density and shedding, while effects on thickness and hair count remain uncertain. Candidacy depends heavily on Norwood or Ludwig staging. The strongest and most consistent evidence appears when PRP is combined with medication, LLLT, or transplantation.
Transparency about off-label status, realistic outcomes, and who is not a good candidate is what separates credible medical guidance from marketing claims of a “70-80% success rate.” The better question for patients is not “Should I get PRP?” but “Where does PRP fit in my personalized, stage-matched plan?”
Schedule a Physician-Led Hair Loss Consultation
Charles Medical Group invites patients to schedule a complimentary consultation with Dr. Glenn Charles for an individualized, stage-based assessment. One visit can evaluate fit across medication, PRP, LaserCap® therapy, scalp micropigmentation, and surgical options (FUE, FUT, and ARTAS®), so patients are not funneled into a single service.
- Phone: 866-395-5544
- Website: charlesmedicalgroup.com
- Locations: Boca Raton and Brickell, Miami, serving Palm Beach, Miami, Fort Lauderdale, and Orlando
- Virtual consultations: Available by FaceTime and Skype for out-of-state and international patients
The practice does not use pressure sales tactics. Every consultation is designed to give patients an honest, realistic picture of what will work for their stage of hair loss.



